KPV (Lys-Pro-Val): Alpha-MSH C-Terminal Fragment and NF-κB Signaling Research
Origin and Discovery
KPV is a synthetic tripeptide corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (α-MSH). Alpha-MSH is a 13-amino acid neuropeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) derived from proopiomelanocortin (POMC) processing. While the central His-Phe-Arg-Trp tetrapeptide (residues 6-9) constitutes the canonical melanocortin receptor-binding pharmacophore, research beginning in the early 2000s identified that the C-terminal KPV tripeptide retains significant biological activity through a melanocortin receptor-independent mechanism.
Chemical Structure
KPV has the sequence Lys-Pro-Val with molecular weight 342.4 Da (molecular formula C₁₆H₃₀N₄O₄). It is one of the smallest bioactive peptides studied in the literature. Key structural features:
- Lysine (Lys): provides a positively charged side chain at physiological pH, critical for electrostatic interactions with target proteins
- Proline (Pro): introduces a rigid kink in the peptide backbone due to its cyclic pyrrolidine ring, constraining the tripeptide into a defined conformation
- Valine (Val): hydrophobic residue contributing to membrane permeability
Notably, KPV lacks high-affinity melanocortin receptor binding, distinguishing its mechanism of action from the parent α-MSH peptide.
Published Research
NF-κB Pathway Modulation
The primary documented mechanism of KPV in the published literature involves inhibition of nuclear factor-kappa B (NF-κB) p65 subunit nuclear translocation. In lipopolysaccharide (LPS)-stimulated macrophage and epithelial cell models, KPV treatment resulted in dose-dependent suppression of NF-κB-driven gene transcription, reducing expression of pro-inflammatory mediators including IL-1β, IL-6, and TNF-α.
Intestinal Epithelial Barrier Research
In vitro studies using Caco-2 and HT-29 intestinal epithelial cell monolayers have examined KPV's effects on transepithelial electrical resistance (TEER) and tight junction protein expression (claudins, occludin, ZO-1) following inflammatory challenge.
PepT1 Transporter Uptake
A significant finding in KPV research was the demonstration that the tripeptide is a substrate for the intestinal peptide transporter PepT1 (SLC15A1). This active transport mechanism enables intracellular accumulation of KPV in epithelial cells, potentially explaining its activity at low extracellular concentrations in cell culture models.
Key Published Studies
- Brzoska T et al. (2008) — Comprehensive review of alpha-MSH and related peptides in inflammatory signaling, published in Endocrine Reviews.
- Laroui H et al. (2012) — Nanoparticle-based delivery of KPV in murine intestinal inflammation models.
Future Research Directions
Current areas of investigation include characterization of the specific intracellular binding target of KPV (the direct molecular target downstream of cellular uptake remains under investigation), its interaction with IKK complex components in the NF-κB activation cascade, and development of PepT1-targeted delivery systems for enhanced cellular uptake in research models.
Available at Crush Research: KPV 10mg. View Certificates of Analysis.
All products are intended for in vitro and laboratory research use only. Not for human or veterinary use.